Biodistribution and Radiation Dosimetry of the Carbonic Anhydrase IX Imaging Agent [18 F]VM4-037 Determined from PET/CT Scans in Healthy Volunteers

Molecular Imaging and Biology

Volumn 16, Issue 5, 2014, Pages 739-746

  Doss, Mohan ^a   Kolb, Hartmuth C ^b   Walsh, Joseph C ^b   Mocharla, Vani P ^b   Zhu, Zhihong ^b   Haka, Michael ^b   Alpaugh, R Katherine ^a   Chen, David Y T ^a   Yu, Jian Q ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b SIEMENS CORPORATE RESEARCH   (United States)

Author keywords

Biodistribution; Carbonic anhydrase IX; Internal dosimetry; PET; 18 F VM4 037

Indexed keywords

EID: 84897254698     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-014-0730-7     Document Type: Article

References (38)

1. Potter C, Harris AL (2004) Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 3:164–167
2. Pastorek J, Pastorekova S (2004) Cancer-related carbonic anhydrase isozymes and their inhibition. CRC, Boca Raton
3. Ivanov S, Liao SY, Ivanova A et al (2001) Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158:905–919
4. Winum JY, Rami M, Scozzafava A et al (2008) Carbonic anhydrase IX: a new druggable target for the design of antitumor agents. Med Res Rev 28:445–463
5. Pastorekova S, Parkkila S, Zavada J (2006) Tumor-associated carbonic anhydrases and their clinical significance. Adv Clin Chem 42:167–216
6. Potter CP, Harris AL (2003) Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 89:2–7
7. Wykoff CC, Beasley NJ, Watson PH et al (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60:7075–7083
8. Chen L, Zhang Z, Kolb HC et al (2012) (1)(8)F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with (1)(8)F-FMISO. Nucl Med Commun 33:1096–1102
9. Ilie M, Mazure NM, Hofman V et al (2010) High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br J Cancer 102:1627–1635
10. Jarvela S, Parkkila S, Bragge H et al (2008) Carbonic anhydrase IX in oligodendroglial brain tumors. BMC Cancer 8:1
11. Bui MH, Seligson D, Han KR et al (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9:802–811
12. Chia SK, Wykoff CC, Watson PH et al (2001) Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 19:3660–3668
13. Loncaster JA, Harris AL, Davidson SE et al (2001) Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61:6394–6399
14. Kaanders JH, Wijffels KI, Marres HA et al (2002) Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62:7066–7074
15. Tanaka N, Kato H, Inose T et al (2008) Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma. Br J Cancer 99:1468–1475
16. Patard JJ, Fergelot P, Karakiewicz PI et al (2008) Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 123:395–400
17. McDonald PC, Winum JY, Supuran CT, Dedhar S (2012) Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget 3:84–97
18. Divgi CR, Uzzo RG, Gatsonis C et al (2013) Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol 31:187–194
19. Neri D, Supuran CT (2011) Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 10:767–777
20. Supuran CT (2008) Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 7:168–181
21. Kolb HC, Walsh JC, Dhanalakshmi K, et al. (2010) Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry. US Patent US20100317842-A1. Issued Dec 16, 2010
22. Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46:1023–1027
23. 18 F-RGD-K5 determined from whole-body PET/CT in monkeys and humans. J Nucl Med 53:787–795
24. FDA (2010) Guidance for industry and researchers. The Radioactive Drug Research Committee: Human Research Without an Investigational New Drug Application. FDA, Silver Spring, MD
25. Stabin M, Stubbs J, Toohey R (1996) Radiation dose estimates for radiopharmaceuticals, NUREG/CR-6345
26. Hasannejad H, Takeda M, Taki K et al (2004) Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther 308:1021–1029
27. Pastorekova S, Parkkila S, Pastorek J, Supuran CT (2004) Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzym Inhib Med Chem 19:199–229
28. Pastorekova S, Casini A, Scozzafava A et al (2004) Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg Med Chem Lett 14:869–873
29. Emara M, Turner AR, Allalunis-Turner J (2010) Hypoxic regulation of cytoglobin and neuroglobin expression in human normal and tumor tissues. Cancer Cell Int 10:33
30. Takacova M, Bartosova M, Skvarkova L et al (2013) Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma. Oncol Lett 5:191–197
31. Betof AS, Rabbani ZN, Hardee ME et al (2012) Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. Br J Cancer 106:916–922
32. Kim SJ, Rabbani ZN, Dewhirst MW et al (2005) Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 49:325–335
33. Kim SJ, Rabbani ZN, Vollmer RT et al (2004) Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res 10:7925–7933
34. Li Y, Wang H, Oosterwijk E et al (2009) Expression and activity of carbonic anhydrase IX is associated with metabolic dysfunction in MDA-MB-231 breast cancer cells. Cancer Invest 27:613–623
35. Wolburg H, Noell S, Fallier-Becker P et al (2012) The disturbed blood–brain barrier in human glioblastoma. Mol Aspects Med 33:579–589
36. McDonald PC, Winum JY, Supuran CT, Dedhar S (2012) Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget 3:84–97
37. 18 F-HX4 in monkeys and humans determined by using whole-body PET/CT. Nucl Med Commun 31:1016–1024
38. 18 F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 15:61–69